Are you a Health Professional? Jump over to the doctors only platform. Click Here

Treating Psoriasis with Etanercept

Print Friendly, PDF & Email

In an article titled ‘Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis’ and published in the June issue of the Archives of Dermatology researchers at the Department of Dermatology, University of Texas Health Center evaluated the safety and efficacy of long-term treatment of psoriasis with etanercept, 50 mg twice weekly.

Researchers designed a phase 3, randomized, double-blind trial with an open-label extension. A total of 618 adult patients with moderate to severe plaque psoriasis were studied at 39 medical centres in the United States and Canada from May 23, 2003, through June 22, 2005. Patients were randomized to receive placebo or etanercept for 12 weeks. Beginning with week 13, all patients (N = 591) received etanercept. Exposure-adjusted adverse event rates were calculated. Efficacy measures included efficacy and patient global assessment of psoriasis. The researchers found that exposure-adjusted rates of adverse events, serious adverse events, infections, and serious infections were similar for placebo and etanercept treatments. Nonneutralizing antibodies to etanercept, observed in 18.3% of patients, had no apparent effect on safety or efficacy. Patients responded within 2 weeks to etanercept, with statistically significant differences in the Psoriasis Area and Severity Index and Dermatology Life Quality Index between the etanercept and placebo groups at week 12. At week 24, after 12 weeks of open-label etanercept treatment, patients in the original placebo group had clinical benefits comparable to those of patients in the original etanercept group. As both groups progressed through the open-label period, the Psoriasis Area and Severity Index response peaked at week 48. At week 96, 51.6% of the original placebo-treated patients and 51.1% of the original etanercept-treated patients had improvements from baseline in the Psoriasis Area and Severity Index of at least 75%. The researchers concluded that extended exposure to 50 mg of etanercept twice weekly resulted in exposure-adjusted rates of adverse events and infections similar to those in patients receiving placebo. Improvements in physician- and patient-reported measures of psoriasis severity were observed for up to 96 weeks of continuous etanercept therapy. (Source: Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A., Arch Dermatol. 2007 Jun;143(6):719-26 : June 2007)


Print Friendly, PDF & Email

Dates

Posted On: 25 June, 2007
Modified On: 16 January, 2014

Tags



Created by: myVMC